Scynexis Inc (SCYX)

$2.64 0.02 (0.56%)

16:00 EDT SCYX Stock Quote Delayed 30 Minutes

Why Is Scynexis (SCYX) Stock Up 69% Today?

By William White, InvestorPlace Writer Mar 30, 2023

Scynexis (SCYX) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

More Articles

Volume:

Previous Close -

Market Cap 96.41M

PE Ratio -1.37

EPS -1.93

Volume (Avg. Vol.) 361,051

Day's Range $2.61 - $2.70

52-Week Range $1.15 - $3.84

Dividend & Yield N/A (N/A)

SCYX Stock Predictions, Articles, and Scynexis Inc News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Jun 1, 2021

Welcome back from the holiday weekend and let's get right into it with a look at the biggest pre-market stock movers for Tuesday.

5 Healthcare Stocks That Are Down, But Not Out!

By Josh Enomoto, InvestorPlace Contributor Aug 29, 2018

Tough headwinds have impacted several healthcare stocks, presenting opportunities for risk-tolerant speculators.

SCYNEXIS stock jumps on licensing anti-fungal for GSK (NASDAQ:SCYX)

From Seeking Alpha Mar 30, 2023

GSK (GSK) and New Jersey-based biotech SCYNEXIS (SCYX) announced an exclusive license agreement on Thursday for Brexafemme (ibrexafungerp tablets), an FDA-approved treatment for...

Anti-Fungus Stock Surges Amid Worries Over Drug-Resistant Strain

From Bloomberg Mar 22, 2023

Scynexis Inc., a pharmaceutical company that develops antifungal medicines, is on track for its largest two-day surge ever on Wednesday following a report of the increasing threat of a drug-resistant fungus spreading in the US.

Deadly fungal infection sweeps across U.S. (NASDAQ:SCYX)

From Seeking Alpha Mar 22, 2023

A rare and often deadly fungal species is fast spreading across the U.S., infectious-disease specialists have warned. The fungus, a type of yeast called Candida auris, first...

SCYX stock jumps as Guggenheim says Buy (NASDAQ:SCYX)

From Seeking Alpha Mar 1, 2023

Scynexis (SCYX) jumped ~23% on Wednesday, after Guggenheim launched its coverage with a Buy rating citing the potential of its antifungal treatment Brexafemme. Read the full story here.

Maxim Group Remains a Buy on SCYNEXIS (SCYX)

From TipRanks Dec 2, 2022

Maxim Group analyst Jason McCarthy maintained a Buy rating on SCYNEXIS (SCYX – Research Report) yesterday and set a price target of $7.00. The comp...

SCYNEXIS (SCYX) Receives a Buy from Ladenburg Thalmann & Co.

From TipRanks Dec 2, 2022

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on SCYNEXIS (SCYX – Research Report) today and set a price target of $15.0...